Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Preferred Stock Liabilities (2018 - 2020)

Outset Medical (OM) has disclosed Preferred Stock Liabilities for 3 consecutive years, with $452.3 million as the latest value for Q2 2020.

  • Quarterly Preferred Stock Liabilities changed N/A to $452.3 million in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $452.3 million through Jun 2020, changed N/A year-over-year, with the annual reading at $409.4 million for FY2019, 4.37% up from the prior year.
  • Preferred Stock Liabilities for Q2 2020 was $452.3 million at Outset Medical, roughly flat from $452.3 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $452.3 million in Q1 2020, with the low at $392.3 million in Q4 2018.
  • Average Preferred Stock Liabilities over 3 years is $423.1 million, with a median of $409.4 million recorded in 2019.
  • Peak annual rise in Preferred Stock Liabilities hit 4.37% in 2019, while the deepest fall reached 4.37% in 2019.
  • Over 3 years, Preferred Stock Liabilities stood at $392.3 million in 2018, then rose by 4.37% to $409.4 million in 2019, then increased by 10.46% to $452.3 million in 2020.
  • According to Business Quant data, Preferred Stock Liabilities over the past three periods came in at $452.3 million, $452.3 million, and $409.4 million for Q2 2020, Q1 2020, and Q4 2019 respectively.